title: Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?
authors.forename: Martin
authors.initials: M
authors.lastname: Lagging
authors.forename: Sa
authors.initials: S
authors.lastname: Alsiö
authors.forename: Kristoffer
authors.initials: K
authors.lastname: Hellstrand
authors.forename: Gunnar
authors.initials: G
authors.lastname: Norkrans
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics / Q000821:virology*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000191:economics; D012367:RNA, Viral / Q000097:blood*; D011994:Recombinant Proteins; D013997:Time Factors; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D012367:RNA, Viral; D011994:Recombinant Proteins